October 03, 2014
Reverse payments between branded- and generic-drug makers don't have to be cash to fall under Actavis, a Pennsylvania federal judge ruled when he remanded a case brought by health insurance companies against AstraZeneca PLC and generic-drug makers alleging a pay-for-delay scheme over generic Nexium.